Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development

Антисмысловые олигонуклеотиды: перспективное направление в открытии и разработке лекарственных средств
Karishma Dhuri, Clara Bechtold, Elias Quijano, Ha T. T. Pham, Anisha Gupta, Ajit Vikram, Raman Bahal
2020-06-26

RNA-targeted therapeuticsantisense oligonucleotideschemical modificationsmicroRNA therapeuticsoligonucleotide delivery
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies.
1
ASO therapies act at the disease-source RNA level, offering an alternative to treatments targeting downstream biological processes.
2
Antisense oligonucleotides bind target RNA sequence-specifically and modulate protein expression through multiple mechanisms.
3
Chemical modifications and optimized delivery strategies are being developed to improve ASO activity, specificity, and therapeutic performance.
4
FDA- and EMA-approved ASO drugs, clinical-stage candidates, and emerging microRNA targets demonstrate expanding therapeutic opportunities for ASO-based treatments.
5
Off-target side effects and insufficient biological activity remain major barriers to translating ASO therapies into clinical success.

Antisense oligonucleotide-based therapies and drugs

Chemical modifications, mechanisms of action, delivery strategies, therapeutic development, and clinical advancement of antisense oligonucleotides

Publication Details
Publication Date
2020-06-26
Journal
Journal of Clinical Medicine
Publisher
Multidisciplinary Digital Publishing Institute
ISSN
2077-0383
Cited by
622
Access Type
Author Information
Authors
Karishma Dhuri
Clara Bechtold
Elias Quijano
Ha T. T. Pham
Anisha Gupta
Ajit Vikram
Raman Bahal
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%